Latest updates for Johnson And Johnson
Fresh curated links around Johnson and Johnson are collected here so marketers can spot useful updates and turn timely ideas into posts faster.
Recent items include:
- Two Paths to Growth: Johnson & Johnson vs AbbVie
- Johnson & Johnson (JNJ) Dividend Stock Analysis
- Dividend Kings In Focus: Johnson & Johnson
Post angles to try
Fresh articles and ideas
Recent curated links from global sources. Generate one free draft from any story, then use SocialBu to schedule and refine your content calendar.
Johnson & Johnson (JNJ) Dividend Stock Analysis
Linked here is a detailed quantitative analysis of Johnson & Johnson (JNJ). Below are some highlights from the above linked analysis: Company Description: Johnson &amp...
Dividend Kings In Focus: Johnson & Johnson
Updated on July 8th, 2026 by Nathan Parsh Only the best companies can increase dividends through multiple recessions. The Dividend Kings are a group of stocks that have increased t...
Johnson & Johnson (JNJ) Presents at Bernstein 42nd Annual Strategic Decisions Conference Transcript
Johnson & Johnson: An Excellent Portfolio Option To Barbell AI, Initiate Buy Rating
J&J gets naming rights to the Johnson & Johnson Exchange at the New Jersey Innovation Hub, Powered by Portal Inn...
Portal Innovations, in partnership with the New Brunswick Development Corporation (DEVCO) and HELIX, announced May 19 that Johnson & Johnson received naming rights to the Johns...
Johnson & Johnson Nabs Naming Rights to New Brunswick’s HELIX Development
Johnson & Johnson is putting its name on the first phase of New Brunswick’s HELIX development, where a new innovation hub will support early-stage life sciences startups with l...
J&J seeks expanded use for drug after positive head and neck cancer study
Why Johnson & Johnson Might Be the Smartest Dividend King to Buy in Today's Market
Johnson & Johnson sells products that are necessities, not just nice-to-haves.
<![CDATA[Pharma M&A Roundup: Gilead Sciences Expands Collaboration with World Health Organization, Johnson &...
Johnson & Johnson to build $1B Florida distribution hub
J&J's billion-dollar infusion will expand a distribution facility in Jacksonville to increase production capacity for Acuvue products and strengthen U.S. operations. The post J...
Johnson & Johnson announces $1B Firefly Bio acquisition to expand oncology pipeline
New Brunswick-based Johnson & Johnson has entered into a definitive agreement to acquire Firefly Bio, Inc., a biotechnology company advancing its proprietary Firelink degrader...
Bristol Myers Squibb vs. Johnson & Johnson: Which Healthcare Stock Is a Better Buy in 2026?
Bristol Myers Squibb leans on specialty medicines and a discounted valuation, while Johnson & Johnson boasts industry-leading margins and cash flow.
Johnson & Johnson Wins Talc Verdict in Oklahoma, Appeal in Pennsylvania
An Oklahoma County District Court jury handed Johnson & Johnson a defense verdict on Wednesday in a talc trial, while a Pennsylvania appeals court affirmed a 2021 win.
Johnson & Johnson (JNJ): Focused on Cancer and Neuroscience as a Top Dividend Aristocrat Stock to Buy
Johnson & Johnson (JNJ) Beats Lawsuit Alleging that Talc caused Three Women’s Cancer
J&J study suggests earlier use of prostate cancer drug improves outcomes
Why Johnson & Johnson (JNJ) Still Fits a Defensive Growth Case
Jim Cramer Explains Johnson & Johnson’s (JNJ) Shares Have Gained
Amid US investment tour, J&J makes $1B stop in Florida to upgrade contact lens plant
With Johnson & Johnson gradually fleshing out its $55 billion U.S. investment scheme in recent months, the New Jersey-headquartered drug and medical device giant on Monday reve...
Laser Photonics Expands into Precision Medical Device Manufacturing with Custom Laser Drilling System Order from Johnson...
$250K Development System Order from Johnson & Johnson Represents Entry into Medical Device Manufacturing; Successful Validation Could Enable Broader Deployment Across Manufactu...
J&J axes eye disease gene therapy after key phase 2b readout
Johnson & Johnson has stopped development of an eye disease gene therapy after reviewing data from one of its key readouts for 2026.
Johnson & Johnson: Stronger Fundamentals, But Too Much Optimism
Turn fresh research into a full content calendar
Use SocialBu to discover ideas, generate post drafts, and schedule them across your social channels.